Real-world clinical genomic analysis of patients with BRAF mutated cancers identifies BRAF class II and III as a population of unmet medical need

Oncogenic BRAF mutations can be categorized into three classes (I, II and III) based on their distinct structural and signaling properties. BRAF inhibitors are approved in select cancer types for patients with Class I mutations. However, there are no approved targeted therapies for patients whose tumors bear BRAF Class II or III mutations. This research utilizes a clinico-genomic database to explore the real-world occurrence, characteristics, and outcomes of patients with oncogenic BRAF mutations by distinct classes across solid tumors.